Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

AbCheck licenses CELEXION yeast display technology for an industry first

AbCheck s.r.o., the multi antibody discovery platforms company, announced today the company has licensed a proven antibody yeast display technology from CELEXION LLC (Cambridge, MA, USA). The addition of this platform to AbCheck's current phage display platform places the company as the World's only antibody discovery specialist leveraging the advantage of working with both phage and yeast display technologies.

14 Mar 2011

New PTLD Guideline highlighted at NCCN Annual Conference

A new Guideline detailing diagnosis, workup, and treatment options for Post-Transplant Lymphoproliferative Disorder, as well as stronger recommendations for therapies in follicular lymphoma, topped the list of highlights in a presentation of the updated NCCN Guidelines for Non-Hodgkin's Lymphomas.

14 Mar 2011

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011

Simcere files IND with SFDA of China for APX003 to treat cancer

Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group, a leading pharmaceutical company in China, filed an Investigational New Drug application with the State Food and Drug Administration of China to evaluate APX003 as a potential cancer therapy.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins. The structure should help instruct the design of a new kind of therapeutics for conditions ranging from Parkinson's disease to inflammation.

11 Mar 2011

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

10 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

Neoprobe reports positive feedback from FDA for RIGScan development

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a successful pre-IND meeting with the U.S. Food and Drug Administration on the development of RIGScan CR, the Company's proprietary radiopharmaceutical for the detection of colorectal cancer tumors.

8 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

A new, rapid blood test that could lead to early diagnosis and potentially save the lives of hundreds of thousands of people stricken with fungal meningitis, a leading cause of AIDS-related deaths in developing countries, is getting closer to market with a recent collaboration between the University of Nevada, Reno and Immuno-Mycologics in Oklahoma.

5 Mar 2011

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

3 Mar 2011

Antibody News and Research

Further Reading

AbCheck licenses CELEXION yeast display technology for an industry first

New PTLD Guideline highlighted at NCCN Annual Conference

Alzheimer's vaccine - First evidence for efficacy

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

Simcere files IND with SFDA of China for APX003 to treat cancer

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

USPTO grants new patent to Intellect's Alzheimer's vaccine

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Neoprobe reports positive feedback from FDA for RIGScan development

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News